Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alkermes plc
  6. Summary
    ALKS   IE00B56GVS15

ALKERMES PLC

(ALKS)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-01 pm EST
28.69 USD   +0.17%
01/17Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday
MT
01/17Alkermes' Melanoma Drug Granted Innovation Passport Designation in UK
MT
01/17Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/26/2023 01/27/2023 01/30/2023 01/31/2023 02/01/2023 Date
28.5(c) 29.02(c) 28.79(c) 28.64(c) 28.69(c) Last
1 037 067 1 162 351 1 130 453 1 169 340 1 094 926 Volume
+0.56% +1.82% -0.79% -0.52% +0.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 098 M - -
Net income 2022 -164 M - -
Net cash position 2022 441 M - -
P/E ratio 2022 -29,3x
Yield 2022 -
Sales 2023 1 169 M - -
Net income 2023 -128 M - -
Net cash position 2023 456 M - -
P/E ratio 2023 -38,8x
Yield 2023 -
Capitalization 4 714 M 4 714 M -
EV / Sales 2022 3,89x
EV / Sales 2023 3,64x
Nbr of Employees 2 211
Free-Float 95,7%
More Financials
Company
Alkermes Public Limited Company is a fully integrated biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. It has a portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a... 
Read more
More about the company
Ratings of Alkermes plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ALKERMES PLC
01/17Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday
MT
01/17Alkermes' Melanoma Drug Granted Innovation Passport Designation in UK
MT
01/17Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa ..
PR
01/17Alkermes plc Awards Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Al..
CI
01/11Transcript : Alkermes plc Presents at 41st Annual J.P. Morgan Healthcare Conf..
CI
01/09Alkermes Plc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/06Alkermes Says it Has Received Interim Award in Arbitration Proceedings With Janssen Pha..
MT
01/06Alkermes Plc. : Other Events (form 8-K)
AQ
2022Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR
2022Transcript : Alkermes plc Presents at Bank of America 2022 Virtual Biotech SM..
CI
2022JPMorgan Adjusts Alkermes Price Target to $29 From $33, Maintains Neutral Rating
MT
2022Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference
PR
2022Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference
PR
2022Mizuho Adjusts Price Target on Alkermes to $36 From $34, Maintains Buy Rating
MT
2022Insider Buy: Alkermes
MT
More news
News in other languages on ALKERMES PLC
01/17Mise à jour sectorielle : Les actions du secteur de la santé son..
01/17Alkermes plc reçoit la désignation de passeport d'innovation par la MHRA (Royaume-Uni) ..
01/06Alkermes déclare avoir reçu une décision provisoire dans la procédure d'arbitrage avec ..
2022Achat d'initiés : Alkermes
2022Alkermes annonce son intention de se séparer de son activité oncologie
More news
Analyst Recommendations on ALKERMES PLC
More recommendations
ETFs positioned on ALKERMES PLCETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
AGFiQ US Market Neutral Anti-Beta Fund - USD18.64%-0.70%United_States
PSYK ETF - USD4.06%-1.18%-NC
First Trust NYSE Arca Biotechnology - Acc - USD3.86%0.25%-United_States
First Trust NYSE Arca Biotechnology Index F...3.55%0.81%United_States
ALPS Medical Breakthroughs ETF - USD3.05%0.74%United_States
More ETFs positioned on ALKERMES PLC
Chart ALKERMES PLC
Duration : Period :
Alkermes plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALKERMES PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 28,69 $
Average target price 32,30 $
Spread / Average Target 12,6%
EPS Revisions
Managers and Directors
Richard F. Pops Chief Executive Officer & Director
Iain Michael Brown Chief Financial Officer & Senior Vice President
Craig C. Hopkinson Chief Medical Officer & EVP-Research & Development
Thomas Harvey Chief Information Officer
Sondra Smyrnios Senior Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ALKERMES PLC9.80%4 714
MODERNA, INC.-1.98%67 639
IQVIA HOLDINGS INC.11.97%42 611
LONZA GROUP AG14.68%42 044
ALNYLAM PHARMACEUTICALS, INC.-4.73%27 854
SEAGEN INC.8.19%25 897